

VIZYLAC RICH SACHET

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.
Abbreviated Prescribing information for VIZYLAC RICH SACHET (Probiotic-Prebiotic & Immunobiotic Powder)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: *Streptococcus faecalis* colonizes the human gut and helps in normalization of gut flora, stimulation of mucosal immunity. *Clostridium butyricum* decreases intestinal pH. *Bacillus mesentericus* selectively stimulates the growth of beneficial anaerobic bacteria and inhibits the growth of pathogenic bacteria. It also helps to decrease secretion of luminal enterotoxin. *Lactobacillus sporogenes* replaces pathogenic organisms in the GI tract by lactobacilli, elicits an immune response, lowers fecal pH, and interferes with the ability of pathogenic bacteria to adhere to intestinal mucosal cells. *Saccharomyces boulardii* the exact mechanism of *Saccharomyces boulardii* is not clearly defined. It may exert a protective effect in the gastrointestinal tract via stimulation of the intestinal secretion of secretory IgA.

DOSAGE AND ADMINISTRATION: As directed by the physician.

CONTRAINDICATION: Hypersensitivity to any of the ingredients, Hypersensitivity to lactose or milk, Immunocompromised state.

WARNINGS & PRECAUTIONS: Patients sensitive to milk should not use lactobacillus products, use in severely ill and malnourished children and use in severely ill adults having terminal illness.

DRUG INTERACTION: No data available.

ADVERSE REACTIONS: Constipation, gas, bloating, itching, hiccups, urticaria, exanthema, quincke's edema and systemic mycosis have been reported.

Chest pain, endocarditis, septicemia have been reported during treatment. However, it is unknown whether these symptoms were due to probiotic therapy or to concomitant antibiotic therapy.

MARKETED BY:

TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

IN/VIZYLAC RICH SACHET 30, 2, 1, 50, 50 Million/APR-2020/01/ABPI

(Additional information is available on request)